Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
05/2000
05/18/2000WO2000027814A1 Avidin derivatives and uses thereof
05/18/2000WO2000027813A1 Azobenzene derivatives as labeling agents and intermediates thereof
05/18/2000WO2000027811A1 Neurotrophic diamide and carbamate agents
05/18/2000WO2000027805A1 Substituted 3,3-diamino-2-propenenitriles, their preparation and use
05/18/2000WO2000027802A1 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof
05/18/2000WO2000027792A1 Novel compounds and medicinal use thereof
05/18/2000WO2000027414A2 Inhibition of the formation of vascular hyperpermeability
05/18/2000WO2000027409A1 Production of a biological factor and creation of an immunologically privileged environment using genetically altered sertoli cells
05/18/2000WO2000027404A1 Method for treating a patient with neoplasia by treatment with an anthracycline antibiotic
05/18/2000WO2000027400A1 Use of agonists of glucocorticosteroid receptors and/or mineral corticosteroid receptors, especially corticosteroids to treat addictions
05/18/2000WO2000027391A1 Method for treating a patient with neoplasia by treatment with a platinum coordination complex
05/18/2000WO2000027387A1 Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis
05/18/2000WO2000027378A2 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases
05/18/2000WO2000027377A2 Phosphinate peptide analogs for the treatment of fibrotic disorders
05/18/2000WO2000027341A2 Novel method of treatment
05/18/2000WO2000027196A1 Use of gm-csf to inhibit development of drug resistance in hiv+ patients
05/18/2000WO2000027194A1 Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
05/18/2000WO2000010553A3 Carbamate and urea compositions and neurotrophic uses
05/18/2000WO2000009560A3 Generation of modified molecules with increased serum half-lives
05/18/2000WO2000009479A3 Heterocyclic thioesters or ketones for vision and memory disorders
05/18/2000WO2000008202A3 3-methylidenyl-2-indolinone modulators of protein kinase
05/18/2000WO2000008193A3 Latency-active regulatory sequences of herpesviruses and latency-inactive herpesvirus for gene transfer
05/18/2000WO2000008141A3 Short oligonucleotides for the inhibition of vegf expression
05/18/2000WO2000008140A3 Antisense oligonucleotides for the inhibition of vegf expression
05/18/2000WO2000007606A3 Methods for increasing the solubility of nutritional materials using probiotic lactic acid-producing bacteria
05/18/2000WO2000006597A3 Endogenous constitutively activated g protein-coupled orphan receptors
05/18/2000WO2000006140A3 Use of moclobemide for treating certain phsychiatric and medical disorders
05/18/2000WO2000004892A3 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
05/18/2000WO2000000207A9 Treatment of hyperproliferative disorders
05/18/2000WO1999061467A3 Inhibition of the binding of protein tyrosine phosphatase pest to domains of signalling proteins
05/18/2000WO1999058096A3 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
05/18/2000DE19945814A1 Verfahren zur Zubereitung eines pharmazeutischen Artemisia-Extraktes und Vorrichtung zur elektrischen Moxibustion unter Verwendung des Extraktes A process for the preparation of a pharmaceutical Artemisia extract and moxibustion device for electrically using the extract
05/18/2000DE19830770C1 Wasserlösliche Zinkpyruvate bzw. deren Hydrate, Verfahren zu ihrer Herstellung und deren Verwendung Water-soluble zinc pyruvate or hydrates thereof, processes for their preparation and their use
05/18/2000CA2350915A1 Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof
05/18/2000CA2350429A1 Neurotrophic diamide and carbamate agents
05/18/2000CA2350388A1 Human hydrolase proteins
05/18/2000CA2350235A1 Tricyclic pyrazole derivatives
05/18/2000CA2350208A1 Antrhranilic acid amides and the use thereof as medicaments
05/18/2000CA2350182A1 Connective tissue growth factor (ctgf) and methods of use
05/18/2000CA2350086A1 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
05/18/2000CA2350071A1 Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis
05/18/2000CA2349951A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof
05/18/2000CA2349904A1 Crf receptor antagonists and methods relating thereto
05/18/2000CA2349814A1 Cytokine signal regulators
05/18/2000CA2349592A1 Use of gm-csf to inhibit development of drug resistance in hiv+ patients
05/18/2000CA2349445A1 Antisense oligomer
05/18/2000CA2348946A1 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases
05/18/2000CA2348934A1 Phosphinate peptide analogs for the treatment of fibrotic disorders
05/18/2000CA2348763A1 Novel compounds and medicinal use thereof
05/18/2000CA2347916A1 Inhibition of the formation of vascular hyperpermeability
05/18/2000CA2346898A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as vegf receptor tyrosine kinase inhibitors
05/18/2000CA2345459A1 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof
05/17/2000EP1000930A2 Tachykinin antagonists
05/17/2000EP1000927A2 Excitatory amino acid receptor modulators
05/17/2000EP1000623A1 Use of epinastine as antitussivum
05/17/2000EP1000621A2 Use of 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz (CD) indoles for treating motion sickness and vomiting
05/17/2000EP1000610A1 Polymers for cosmetic formulations
05/17/2000EP1000166A2 Inhibitors of cell-cycle progression and uses related thereto
05/17/2000EP1000163A1 $i(PSEUDOMONAS) EXOTOXIN A-LIKE CHIMERIC IMMUNOGENS
05/17/2000EP1000085A1 Treatment of insulin resistance with growth hormone secretagogues
05/17/2000EP1000067A1 Thiazolobenzoheterocycles, preparation and medicines containing same
05/17/2000EP1000066A1 Fused 1,2,4-thiadiazine derivatives, their preparation and use
05/17/2000EP1000064A1 Compounds
05/17/2000EP1000062A1 Tricyclic vasopressin agonists
05/17/2000EP1000061A1 Therapeutically active 1,2,4-triazolo(4,3-b) pyridazine derivatives as ligands for gaba receptors
05/17/2000EP1000059A1 Tricyclic vasopressin agonists
05/17/2000EP1000056A1 6-pyrrolidin-2-ylpyrindine derivatives, their preparation and application in therapy
05/17/2000EP1000055A1 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
05/17/2000EP1000048A1 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
05/17/2000EP1000047A1 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring
05/17/2000EP1000046A1 Piperazine derivatives active on the lower urinary tract
05/17/2000EP1000045A1 1,4-disubstituted piperazines
05/17/2000EP1000044A1 Benzothia(oxa)diazol derivatives and their use as endothelin-receptor antagonists
05/17/2000EP1000041A1 1,3-diaza- heterocycles and their use as nitric oxide synthase inhibitors
05/17/2000EP1000040A1 Il-5 inhibiting 6-azauracil derivatives
05/17/2000EP1000039A1 Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
05/17/2000EP1000035A1 Substituted 6-phenylphenanthridines
05/17/2000EP1000034A1 Substituted 6-alkylphenanthridines
05/17/2000EP1000033A1 Heterocyclic derivatives which inhibit factor xa
05/17/2000EP1000031A1 Vitronectin receptor antagonist
05/17/2000EP1000029A1 (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders
05/17/2000EP1000028A1 Gastrokinetic monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
05/17/2000EP1000024A1 Mercaptoacylamino acids as metallo-beta-lactamase inhibitors
05/17/2000EP1000023A2 Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same
05/17/2000EP1000018A2 Urokinase inhibitors
05/17/2000EP1000017A1 Il-8 receptor antagonists
05/17/2000EP1000015A1 Bicyclic metabotropic glutamate receptor ligands
05/17/2000EP1000012A1 Process for converting propargylic amine-n-oxides to enaminones
05/17/2000EP0999849A1 Therapeutic agent for the treatment of septicaemia, its preparation and use
05/17/2000EP0999845A1 Treatment of diabetes with thiazolidinedione and sulphonylurea
05/17/2000EP0999842A1 Novel substituted imidazole compounds
05/17/2000EP0999841A1 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine
05/17/2000EP0999835A1 Imidazole derivatives as mdr modulators
05/17/2000EP0999834A1 Antithrombotic agents
05/17/2000EP0999757A1 Nutritional composition for subjects under stress
05/17/2000EP0791011B1 Biologically active tgf-beta1 and tgf-beta2 peptides
05/17/2000EP0773950A4 Linked peptide nucleic acids
05/17/2000EP0726768B1 Use of nitric oxide releasing compounds for the manufacture of a medicament for protection in ischemia reperfusion injury
05/17/2000CN1253586A Compositions and methods for diagnosing/treating disease based on beta-catenin/transcription actor interactions
05/17/2000CN1253565A Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines
1 ... 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 ... 1564